— The T cell therapy company heads to ASH 2024 next month to introduce its novel allogeneic protection and cytokine engineering strategies to support the development of potent and persistent...

Data to be presented from an oral azacitidine plus cedazuridine (ASTX030) combination phase 1 open-label dose escalation and expansion trial Findings to be shared from a study analyzing...

- Initial data from the ongoing Phase 1b study evaluating R289, a dual IRAK1/4 inhibitor, in LR-MDS - Additional data for REZLIDHIA® (olutasidenib) in patients with mIDH1 AML and MDS SOUTH SAN...

Pre-clinical data demonstrate robust anti-tumor activity and a novel off-the-shelf approach for GPC3+ solid tumors PHILADELPHIA, Nov. 5, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq:...

Collaboration focused on helping repairers easily identify OEM-recommended calibrations for collision-damaged vehicles equipped with Advanced Driver-Assistance Systems (ADAS) SAN DIEGO and...